Polymorphism of the serotonin receptor type (5-HTR2A) gene and verbal fluency in normalcy and schizophrenia

Molekulyarnaya Biologiya

Volumn 37, Issue 1, 2003, Pages 68-73

  Alfimova, M V ^a   Golimbet, V E ^a   Mityushina, N G ^a  

^a MENTAL HEALTH RESEARCH CENTER   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA; SEROTONIN RECEPTOR TYPE 2A GENE; SEROTONINERGIC SYSTEM; VERBAL BEHAVIOR; ADOLESCENT; ADULT; AGED; FEMALE; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE; RUSSIAN FEDERATION; SPEECH; SPEECH DISORDER;

SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MOSCOW; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; REFERENCE VALUES; SCHIZOPHRENIA; SPEECH; SPEECH DISORDERS;

EID: 0038343447     PISSN: 00268984     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Robert P.H., Lafont V., Medecin I. et al. 1998. Clustering and switching strategies in verbal fluency tasks: comparison between schizophrenics and healthy adults. J. Int. Neuropsychol. Soc. 4, 539-546.
2. Curtis V.A., Bullmore E.T., Brammer M.J. et al. 1998. Attenuated frontal activation during a verbal fluency task in patients with schizophrenia. Am. J. Psychiatry. 155, 1056-1063.
3. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. 1995. Clin. Neurosci. 3, 64-75.
4. Kasper S., Tauscher J., Kufferle B., Barnas C., Pezawas L., Quiner S. 1999. Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 249 (Suppl. 4), 83-89.
5. Buchanan R.W., Holstein C, Breier A. 1994. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry. 36, 717-725.
6. Lee M.A., Thompson P.A., Meltzer H.Y. 1994. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry. 55 (Suppl B), 82-87.
7. Hoff A.L., Faustman W.O., Wieneke M. et al. 1996. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology. 15, 361-369.
8. Meltzer H.Y., Thompson P.A., Lee M.A., Ranjan R. 1996. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology. 14 (Suppl. 3), 27S-33S.
9. McGurk S.R. 1999. The effects of clozapine on cognitive functioning in schizophrenia. J. Clin. Psychiatry. 60 (Suppl. 12.), 24-29.
10. Potkin S.G., Fleming K., Jin Y., 2001. Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J. Clin. Psychopharmacol. 21, 479-483.
11. Galletly C.A., Clark C.R., McFarlane A.C., Weber D.L. 1997. Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine. Psychiatry Res. 72, 161-166.
12. Kempler D., Teng E.L., Dick M., Taussig I.M., Davis D.S. 1998. The effects of age, education, and ethnicity on verbal fluency. J. Int. Neuropsychol. Soc. 4, 531-538.
13. Mejia S., Pineda D., Alvarez L.M., Ardila A. 1998. Individual differences in memory and executive function abilities during normal aging. Int. J. Neurosci. 95, 271-284.
14. Dean B., Hayes W. 1996. Decreased frontal cortical serotonin 2A receptors in schizophrenia. Schizophr. Res. 21, 133-139.
15. Mita T., Hanada S., Nishino N. et al. 1986. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol. Psychiatry. 21, 1407-1414.
16. Dean B., Hussain T., Hayes W. et al. 1999. Changes in serotonin 2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J. Neurochem. 72, 1593-1599.
17. Williams J., Spurlock G., Mc Guffin P. et al. 1996. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. Eur. Multicentre association study of Schizophrenia (EMASS) Group. Lancet. 347, 9011.
18. Joober R., Bendelfat C., Brisebois K. et al. 1999. T102C polymorphism in the 5HTR2A gene and schizophrenia: relation to phenotype and drug response variability. J. Psychiatry Neurosci. 24, 141-146.
19. Lehrer B., Segman R.H. 2000. Effect of age on the relationship of the dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia. World J. Biol. Psychiatry. 2 (Suppl. 1), 31S.
20. Tan E., Chong S., Mahendran R., Dong F., Tan Ch. 2001. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol. Psychiatry. 50, 144-147.
21. Arranz M.J., Munro J., Sham P. et al. 1998. Meta-analysis of studies on genetic variation in 5-HTR2a receptors and clozapine response. Schizophr. Res. 32, 93-99.
22. Kay S.R., Fizbein A., Opler L.A. 1997. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261-276.
23. Warren J.T., Peacock M.L., Rodrigues L.C., Fink A.G. 1993. An Msp1 polymorphism in the human serotonin receptor gene (5HTR2A): detection by DGGE and FLP analysis. Human. Mol. Genet. 2, 338.
24. Herlitz A., Nilsson L.G., Backman L. 1997. Gender differences in episodic memory. Mem. Cognit. 25, 801-811.
25. Goldstein J.M., Seidman L.J., Goodman J.M. et al. 1998. Are there sex differences in neuropsychological functions among patients with schizophrenia? Am. J. Psychiatry. 155, 1358-1364.
26. Van Goozen S.H., Cohen-Kettenis P.T., Gooren L.J., Frijda N.H., Van de Poll N.E. 1994. Activating effects of androgens on cognitive performance: causal evidence in a group of female-to-male transsexuals. Neuropsychologia. 32, 1153-1157.
27. Eastwood S.L., Burnet P.W., Gittins R., Baker K., Harrison P.J. 2001. Expression of serotonin 5-HT(2A) receptors in the human cerebellum and alterations in schizophrenia. Synapse. 42, 104-114.
28. Shinkai T., Ohmory O., Suzuki T. et al. 2001. Polymorphisms of tryptophan hydroxylase gene and the symptomology of schizophrenia: an association study. Am. J. Med. Genet. 105, 620-621.
29. Berman I., Viegner B., Merson A., Allan E., Pappas D., Green A.I. 1997. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr. Res. 25, 1-10.
30. O'Leary D.S., Flaum M., Kesler M.L., Flashman L.A., Arndt S., Andreasen N.C. 2000. Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J. Neuropsychiatry Clin. Neurosci. 12, 4-15.
31. Allen H.A., Liddle P.P., Frith C.D. 1993. Negative features, retrieval processes and verbal fluency in schizophrenia. Br. J. Psychiatry. 163, 769-775.
32. Joyce E.M., Collinson S.L., Crichton P. 1996. Verbal fluency in schizophrenia: relationship with executive function, semantic memory and clinical alogia. Psychol. Med. 26, 39-49.
33. Baare W.F., Pol H.E., Hijman R., Mali W.P., Viergever M.A., Kahn R.S. 1999. Volumetric analysis of frontal lobe regions in schizophrenia: relation to cognitive function and symptomatology. Biol. Psychiatry. 45, 1597-1605.
34. Alpert M., Kotsaftis A., Pouget E.R. 1997. Speech fluency and schizophrenic negative signs. Schizophr. Bull. 23, 171-177.